Navigation Links
Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis

- Topical Therapy Reduces TNF-alpha Production Through Inhibition of PDE-4 Enzyme

PALO ALTO, Calif., June 06, 2007 /PRNewswire/ -- Anacor Pharmaceuticals, a privately held pharmaceutical company, announced today the results from its placebo-controlled Phase 1 trial of AN2728, a first-in-class topical therapy under investigation for the treatment of psoriasis. The trial showed AN2728 to be well-tolerated, with activity comparable to existing topical treatments for psoriasis.

AN2728 is the product of a focused medicinal chemistry effort to create small molecules that inhibit TNF-alpha, the inflammatory cytokine that is the target of the powerful monoclonal antibodies now marketed for the treatment of psoriasis. Company researchers have shown that AN2728 suppresses the phosphodiesterase 4 (PDE4) enzyme, leading to TNF-alpha inhibition.

"This early-stage trial demonstrated definitive anti-inflammatory activity in humans. We are encouraged that the compound decreases TNF-alpha, a cytokine known to be important in psoriasis, by the inhibition of PDE4, a well-validated anti-inflammatory target," said Karl Beutner, Anacor's chief medical officer. "A topical compound that effectively targets TNF-alpha would have great promise, and we intend to initiate further clinical trials to characterize the clinical utility of this drug in psoriasis and other inflammatory skin diseases."

Psoriatic plaques on each of the 12 patients enrolled in the trial were divided into six sections, and each of those sections was treated with a different therapy: AN2728 ointment, AN2728 cream, betamethasone, tacrolimus (Protopic) and vehicle cream and ointment. Using ultrasound, researchers measured the thickness of the inflammatory infiltrate in the psoriatic plaques and also recorded the clinical response based on an investigator global evaluation of disease severity.

As measured by decreases in the thickness of the infiltrate and clinical scores, AN2728-treated plaques improved significantly compared with vehicle treatment (p<0.001), and efficacy was comparable to that seen with betamethasone and tacrolimus. AN2728 treatment was well-tolerated in all patients.

About Psoriasis

Psoriasis is an inflammatory skin disorder that affects approximately 14 million individuals worldwide. The disorder ranges from a single, small, localized lesion in some patients to a severe, disfiguring skin condition that may be associated with disabling arthritis.

About Anacor Pharmaceuticals

Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory, fungal and bacterial diseases based on its proprietary, small-molecule, boron-based chemistry. The company's lead product is AN2690, which is in Phase 2 trials for onychomycosis, a fungal infection of the nail and nailbed. Ancor has entered into an exclusive, worldwide agreement with Schering-Plough Corporation to develop and commercialize the drug. The company is also conducting clinical trials with two anti-inflammatory product candidates, AN2728 and AN0128

CONTACT: David Perry, Chief Executive Officer of Anacor Pharmaceuticals,+1-650-739-0700; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, , for Anacor PharmaceuticalsInc. breid@weisscommpartners.com

Web site: http://www.anacor.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... today announced that it has implemented a ... the Zimmer Biomet management team. Effective January 23, ... the position of President, Americas and join the ... served as Zimmer Biomet,s Vice President of U.S. ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... BELLEFONTE, Pa. , Jan. 17, 2017 /PRNewswire/ ... Medical, Inc.(AMI) announces the addition of 6 senior ... of the TubeClear® System.  These sales leaders were ... recently acquired medical device company. Repeatedly recognized for ... of exceeding customer expectations and establishing relationships with ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Livionex, ... the results of a double blind clinical study for its dental gel that shows ... leading national brand of toothpaste containing triclosan. The study was conducted at the Beckman ...
Breaking Medicine News(10 mins):